Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Vectura Group plc announces a key appointment to support innovation, customer focus and growth as the company continues with its strategic development as a leading inhalation specialist in the pharmaceutical services space.
New physicians bring clinical expertise in pediatrics and women with epilepsy
TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, announces the appointment of 2 senior executives and 2 independent board members.
Using artificial intelligence and machine learning, the collaboration will focus on delivering new technology to help enable faster delivery of medical therapies to the biotech and pharma industries
Renowned drug discovery leader to guide alliance formed to improve scientific exchange in UK drug discovery community
Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
There’s a growing demand for life sciences professionals in Massachusetts, but a new report indicates that the home-grown talent pipeline is not adequate enough to meet the growing demands in the Bay State.
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
This morning, San Diego-based Illumina, Inc. announced that Gottlieb joined its board of directors effective Feb. 4.
Even as lawmakers debate and malign proposed plans to lower the costs of prescription drugs in the United States, since the start of the year, prices have increased on more than 600 prescription drugs by an average of 5.2%.